# AOD9604 FAQ: Common Questions Answered from the Research Record

> AOD9604 frequently asked questions — mechanism, dosage, safety, regulatory status, and comparisons — answered directly from the published clinical and preclinical literature.

## AOD9604 Frequently Asked Questions

The AOD9604 questions below are answered directly from the published research record. Every quantitative claim is cited. Every answer on this page starts with the finding, not the hedge.

## What is AOD9604?

AOD9604 is a 16-amino-acid synthetic peptide fragment of human growth hormone — specifically the C-terminal residues 177–191 with an N-terminal tyrosine substituted for native phenylalanine. Molecular weight: 1815.1 Da. CAS: 221231-10-3. Originally developed as an anti-obesity investigational drug by Metabolic Pharmaceuticals (Australia). Distinct from full hGH: it does not activate the GH receptor and does not raise IGF-1 levels [1][2].

## Does AOD9604 actually work?

In preclinical rodent models: yes, consistently. Dose-dependent lipolysis, inhibition of lipogenesis, and fat reduction without lean-mass loss were reproducible across multiple designs [1][3]. In human Phase IIa at 1 mg/day: a modest but statistically significant weight-loss advantage over placebo at 12 weeks (2.8 kg vs 0.8 kg) [7]. In human Phase IIb at 24 weeks: the primary weight-loss endpoint was not met at any dose versus placebo [8]. The clinical efficacy data is mixed; the preclinical mechanism data is solid.

## How much weight can you lose on AOD9604 peptide?

The Phase IIa trial 1 mg/day group lost a mean of 2.8 kg over 12 weeks versus 0.8 kg for placebo [7]. The Phase IIb OPTIONS study did not show statistically significant weight loss over placebo at 24 weeks [8]. Preclinical rodent studies showed consistent dose-dependent fat reduction, but these outcomes did not translate to the primary human endpoint in the larger, longer trial. There is no validated human weight-loss number from a Phase III study — no Phase III was conducted.

## How long does it take for AOD9604 to start working?

Research protocols studied response windows of 12–24 weeks. Preclinical models showed measurable lipolytic effects within 2–4 weeks of continuous treatment [1][10]. No validated human onset-of-effect timeline exists from controlled trials. Pharmacokinetic data shows peak plasma concentration at approximately 60 minutes post-oral-dose in pig models [10], but that is a PK parameter, not an efficacy onset figure.

## What cycle lengths were studied in research?

The longest published human study was 24 weeks (Phase IIb OPTIONS) [8]. Chronic animal toxicology studies ran up to 6–9 months [9]. No adverse long-term safety signals were identified in any published window. Research beyond 24 weeks in humans has not been published.

## Is AOD9604 safe to take?

Clinical trial aggregate across six trials and approximately 900 subjects: no serious drug-related adverse events, no drug-related withdrawals, adverse event profile indistinguishable from placebo. Zero anti-drug antibodies. No IGF-1 elevation. No glucose disruption [4][5][6][13]. That is the available safety data. It does not constitute a clinical recommendation.

## What are the side effects of AOD9604?

Documented in clinical trials: mild headache (most common, equal to placebo frequency), transient GI effects (diarrhea, flatulence, nausea, all mild-to-moderate and self-resolving), and injection-site reactions (redness, swelling, mild pain) when subcutaneous route was used [4]. Notably absent: no blood glucose disruption, no IGF-1 elevation, no immunogenic response.

## What are the side effects of AOD9604 peptide?

Same adverse event profile as above — the oral and IV route data cover the same compound. Mild headache and transient GI symptoms were the most frequently noted events across approximately 900 subjects in six trials [4]. All events were mild-to-moderate and resolved without intervention. The safety profile is notably clean relative to the compound's research history.

## What happened when you stop taking AOD9604?

No rebound or withdrawal effects were documented in any clinical trial discontinuation period [20]. AOD9604 has no HPA-axis receptor agonism and no mechanism by which physiological dependency would develop. No withdrawal adverse events were reported in any study window across approximately 900 subjects [13].

## What is the difference between HGH fragment 176-191 and AOD9604?

Functionally the same molecule. AOD9604 is the pharmaceutical development name; HGH Frag 176-191 is the common research community name. Residue numbering differences (176 vs 177) reflect whether the N-terminal tyrosine is counted in the sequence. Both refer to the same C-terminal hGH fragment with an N-terminal tyrosine substitution [1][5]. CAS 221231-10-3 is the authoritative identifier.

## Does AOD9604 work for weight loss?

In preclinical rodent models: yes — dose-dependent lipolysis and inhibition of lipogenesis, reproducibly [1][3]. In Phase IIa human trial at 1 mg/day: modest but statistically significant advantage over placebo at 12 weeks [7]. In Phase IIb human trial: primary weight-loss endpoint not met versus placebo at 24 weeks [8]. Lipid metabolism parameters improved as secondary markers. The net answer: preclinical yes; human primary endpoint no.

## What is the half-life of AOD9604?

IV half-life approximately 3 minutes in pig pharmacokinetic studies [18]. Oral Tmax approximately 60 minutes post-dose in pig studies [10]. No peer-reviewed subcutaneous human half-life has been published. Researchers citing specific subcutaneous human half-life values are extrapolating beyond the published literature.

## Does AOD9604 need to be refrigerated?

As a lyophilized peptide, research-grade AOD9604 is typically stored frozen (-20°C) in powder form, with reconstituted solution stored refrigerated (2–8°C) [9]. Specific stability data under various storage conditions has not been published in the primary clinical literature.

## Is AOD9604 FDA-approved for weight loss?

No. AOD9604 is not FDA-approved for any indication. The development program was discontinued in 2007 after the Phase IIb trial did not meet its primary obesity endpoint [8][17]. It is not a DEA-controlled substance. Its 503A compounding pharmacy eligibility was under FDA PCAC review as of December 2024, with the nominator having withdrawn the nomination in September 2024 [RS1].

## Is AOD9604 a steroid?

No. AOD9604 is a 16-amino-acid peptide. It does not have a steroidal four-ring backbone and does not activate androgen, estrogen, or glucocorticoid receptors. It is structurally derived from hGH but activates distinct adipocyte-level pathways via the beta3-adrenergic receptor, not the GH receptor [1][2].

## Is AOD9604 legal?

In the US: not a DEA-controlled substance. Not on the FDA drug approval list. 503A compounding pharmacy status under regulatory review as of December 2024 [RS1]. In Australia: TGA-assessed. WADA status: explicitly classified under S2.2.3 (Growth Hormone fragments) on the 2026 WADA Prohibited List — prohibited at all times in competitive sport; detectable by accredited anti-doping laboratories [14][15][RS2]. Researchers in sport contexts should treat it as prohibited and consult current WADA guidance directly.

## Does AOD9604 raise IGF-1 like HGH?

No. This is the pharmacological distinction. Full hGH activates the GH receptor and downstream IGF-1 production. AOD9604 lacks the GH receptor-binding domain. Multiple clinical studies confirmed no IGF-1 elevation at any tested dose across all six human trials [5]. p = 0.75754 in the 24-week OPTIONS study IGF-1 analysis.

## Why was AOD9604 discontinued as a pharmaceutical drug?

The Phase IIb OPTIONS study (502 subjects, 24 weeks) did not demonstrate statistically significant weight loss versus placebo [8]. Without Phase IIb efficacy data, no Phase III investment was made. Program terminated 2007. Safety was not the reason — the safety record was excellent [17].

## How does AOD9604 stimulate lipolysis without affecting the HGH receptor?

Via beta3-adrenergic receptor-mediated signaling in adipocytes. AOD9604 activates adenylyl cyclase → elevated cAMP → PKA activation → HSL phosphorylation and activation → triglyceride hydrolysis. ACC is simultaneously suppressed, inhibiting lipogenesis [2][3]. This pathway is independent of the GH receptor; AOD9604 does not bind it. The knockout mouse data confirms the beta3-AR requirement [2].

## Does AOD9604 affect insulin or blood sugar levels?

No significant effect. Oral glucose tolerance testing across all human AOD9604 clinical trials showed no significant changes from baseline at any dose [6]. A trend toward benefit — reduced prevalence of impaired glucose tolerance — was observed in the 1 mg/day Phase IIa group [21]. No insulin resistance was detected. No pancreatic beta-cell dysfunction was documented.

## Does AOD9604 help with cartilage repair and osteoarthritis?

Preclinical data is positive but limited. Intra-articular injection in a rabbit OA model reduced lameness recovery time; combined with hyaluronic acid, the effect on cartilage morphology and histopathology was the largest in that study [11]. In vitro bovine chondrocytes showed increased proteoglycan and collagen production [12]. No human osteoarthritis trials have been published. This is an active preclinical research direction, not a validated clinical finding.

## What happened to AOD9604 in the Phase IIb clinical trial?

METAOD006 (OPTIONS): 502 obese adults, four arms (0.25/0.5/1.0 mg/day oral and placebo), 24 weeks. Weight loss was not statistically significantly different from placebo at any dose at the primary endpoint. Safety was confirmed — no serious adverse events, no antibody formation. The trial demonstrated excellent safety but insufficient efficacy to continue clinical development [8].

## Is AOD9604 on the WADA prohibited list?

Yes. AOD9604 is classified under WADA 2026 Prohibited List Section S2.2.3 — Growth Hormone, its analogues and fragments. The classification covers AOD9604 by name and as an HGH-derived fragment under the class prohibition. Prohibited at all times in competitive sport [RS2]. Validated urine detection methods exist with a stable CRSVEGSCG metabolite extending detection windows [14].

## How does AOD9604 compare to CJC-1295 for fat loss?

Different mechanisms entirely. CJC-1295 is a GHRH analog that stimulates pituitary GH release (and secondarily IGF-1), producing broad metabolic and anabolic effects. AOD9604 acts directly at adipocytes via beta3-AR without GH-axis involvement — it does not raise GH or IGF-1 [16]. The two are not equivalent for fat-loss research purposes and do not share a mechanistic pathway.

## Can AOD9604 be stacked with ipamorelin?

No published clinical or preclinical studies examine AOD9604 plus ipamorelin co-administration. Their mechanisms are distinct: AOD9604 acts directly at adipocytes via beta3-AR; ipamorelin is a GH secretagogue acting at GHS-R1a to pulse GH release [16]. Safety and pharmacokinetic interaction profile is uncharacterized in the research literature.

## Does AOD9604 preserve muscle mass while burning fat?

Preclinical obese rodent studies showed fat reduction without significant lean-mass loss [1][19]. The absence of GH receptor activation means the anabolic muscle-growth signal is not present, but neither is the catabolic stress-signaling seen with some interventions. Human body composition data beyond weight change was not fully characterized in the published Phase IIa/IIb record.

## Is AOD9604 oral bioavailable or does it have to be injected?

Both routes have published data. Oral bioavailability was estimated at approximately 40% in rat models — unusual for a peptide [9]. The Phase IIa and IIb human trials used encapsulated oral tablets at 0.25–1.0 mg/day [7][8]. Intravenous administration was used in Phase I dose-escalation studies [4]. Subcutaneous injection is used in research settings; no published human pharmacokinetic data for this route exists.

## What is the best time to take AOD9604?

Clinical trials used fasting-state or meal-relative-timed oral administration. The published protocols do not isolate timing as an independent variable; no direct comparative timing study has been published for AOD9604. The fasting-state rationale is based on peptide absorption kinetics theory, not AOD9604-specific controlled timing data.

## Why is AOD9604 not commonly used in human medicine if it was found safe?

Regulatory drug approval requires demonstrated safety AND efficacy in a Phase III trial. AOD9604 had strong safety data from Phase I/II, but the Phase IIb obesity trial did not demonstrate sufficient efficacy to justify Phase III investment [17]. Safety alone does not qualify a drug for approval. This is a common misconception: a strong safety record is a necessary condition for approval, but the sufficient condition is Phase III efficacy evidence, which AOD9604 never had the opportunity to generate.

## What works better for weight loss — HGH or peptides like AOD9604?

Full hGH has documented lipolytic activity in clinical settings but activates the GH receptor broadly, raising IGF-1 and carrying significant side effects including glucose dysregulation and fluid retention. AOD9604 was designed to isolate the lipolytic domain without receptor-level effects. Full hGH had a clinical efficacy signal that AOD9604's isolated fragment did not replicate in the Phase IIb obesity trial [19][16]. The metabolic safety advantage of AOD9604 over full hGH is documented preclinically; the human efficacy comparison favors neither compound for the obesity indication as neither has an approved human indication for weight loss.

---

The AOD9604 spec sheet — sixteen residues, six trials, one discontinued program, read from the primary sources and held by no clinic.